UA117045C2 - Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування - Google Patents
Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосуванняInfo
- Publication number
- UA117045C2 UA117045C2 UAA201606954A UAA201606954A UA117045C2 UA 117045 C2 UA117045 C2 UA 117045C2 UA A201606954 A UAA201606954 A UA A201606954A UA A201606954 A UAA201606954 A UA A201606954A UA 117045 C2 UA117045 C2 UA 117045C2
- Authority
- UA
- Ukraine
- Prior art keywords
- hybrid protein
- growth
- fusion protein
- inhibiting angiogenesis
- protein inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Винахід стосується гібридного білка для пригнічення ангіогенезу або судинного росту, який складається з фрагмента рецептора VEGF людини та Fc-фрагмента імуноглобуліну людини. Також винахід стосується нуклеотидної послідовності, що кодує гібридний білок, вектора експресії, клітини-хазяїна, що експресує гібридний білок, способу одержання гібридного білка, фармацевтичної композиції, що містить гібридний білок, та застосування гібридного білка для виготовлення лікарського засобу для лікування захворювання, спричиненого ангіогенезом або судинним ростом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410035738 | 2014-01-25 | ||
PCT/CN2015/071434 WO2015110067A1 (zh) | 2014-01-25 | 2015-01-23 | 一种抑制血管新生或生长的融合蛋白及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA117045C2 true UA117045C2 (uk) | 2018-06-11 |
Family
ID=53680846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201606954A UA117045C2 (uk) | 2014-01-25 | 2015-01-23 | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування |
Country Status (18)
Country | Link |
---|---|
US (1) | US9657084B2 (uk) |
EP (1) | EP3098241B1 (uk) |
JP (1) | JP6071099B1 (uk) |
KR (1) | KR101789501B1 (uk) |
CN (1) | CN104804097B (uk) |
AU (1) | AU2015208482B2 (uk) |
BR (1) | BR112016015187A2 (uk) |
CA (1) | CA2935610C (uk) |
ES (1) | ES2648809T3 (uk) |
HK (1) | HK1212716A1 (uk) |
IL (1) | IL246528B (uk) |
MX (1) | MX368442B (uk) |
NZ (1) | NZ721607A (uk) |
PE (1) | PE20170142A1 (uk) |
RU (1) | RU2634406C1 (uk) |
UA (1) | UA117045C2 (uk) |
WO (1) | WO2015110067A1 (uk) |
ZA (1) | ZA201604362B (uk) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060217311A1 (en) | 2005-03-25 | 2006-09-28 | Daniel Dix | VEGF antagonist formulations |
CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
SG191334A1 (en) | 2011-01-13 | 2013-08-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2017084616A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
CN106279435B (zh) * | 2016-08-16 | 2019-06-07 | 新乡医学院 | 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用 |
WO2019083171A2 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |
KR20200085752A (ko) * | 2017-11-10 | 2020-07-15 | 에센 인스트루먼츠, 인크. 디/비/에이/ 에센 바이오사이언스, 인크. | 생세포 시각화 및 분석 |
KR20200112893A (ko) | 2018-01-26 | 2020-10-05 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-vegf 제제를 사용한 혈관신생 장애의 치료 방법 및 조성물 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
JP2023502501A (ja) | 2019-11-25 | 2023-01-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 眼内血管新生のための長時間作用型vegf阻害剤 |
CN116715749B (zh) * | 2023-03-20 | 2024-04-09 | 吉林大学 | 一种与胶原具有特异结合能力vegf活性抑制蛋白及其制备方法与应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1608685B1 (en) | 2003-03-28 | 2007-02-21 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists for the treatment of diabetes |
EP1626989A2 (en) | 2003-05-28 | 2006-02-22 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
WO2005121176A1 (fr) | 2004-06-08 | 2005-12-22 | Chengdu Kanghong Biotechnologies Co. Ltd | Proteine chimerique inhibitrice d'angiogenese et utilisation associee |
EP1753442A2 (en) * | 2004-06-10 | 2007-02-21 | Regeneron Pharmaceuticals, Inc. | Method of administering and using vegf inhibitors for the treatment of human cancer |
CN100471872C (zh) * | 2005-11-04 | 2009-03-25 | 余波 | 包含vegf受体片段的优化融合蛋白质及其医疗应用 |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN101279092B (zh) * | 2007-04-02 | 2010-10-27 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用 |
CN101838329A (zh) | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
-
2015
- 2015-01-23 RU RU2016126023A patent/RU2634406C1/ru active
- 2015-01-23 PE PE2016001099A patent/PE20170142A1/es unknown
- 2015-01-23 WO PCT/CN2015/071434 patent/WO2015110067A1/zh active Application Filing
- 2015-01-23 MX MX2016008776A patent/MX368442B/es active IP Right Grant
- 2015-01-23 US US15/109,422 patent/US9657084B2/en active Active
- 2015-01-23 AU AU2015208482A patent/AU2015208482B2/en active Active
- 2015-01-23 NZ NZ721607A patent/NZ721607A/en unknown
- 2015-01-23 JP JP2016544126A patent/JP6071099B1/ja active Active
- 2015-01-23 EP EP15739893.4A patent/EP3098241B1/en active Active
- 2015-01-23 CA CA2935610A patent/CA2935610C/en active Active
- 2015-01-23 ES ES15739893.4T patent/ES2648809T3/es active Active
- 2015-01-23 CN CN201510036141.3A patent/CN104804097B/zh active Active
- 2015-01-23 UA UAA201606954A patent/UA117045C2/uk unknown
- 2015-01-23 KR KR1020167017551A patent/KR101789501B1/ko active IP Right Grant
- 2015-01-23 BR BR112016015187-9A patent/BR112016015187A2/pt active Search and Examination
-
2016
- 2016-01-21 HK HK16100677.2A patent/HK1212716A1/zh unknown
- 2016-06-28 ZA ZA2016/04362A patent/ZA201604362B/en unknown
- 2016-06-29 IL IL246528A patent/IL246528B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
PE20170142A1 (es) | 2017-04-02 |
IL246528B (en) | 2018-01-31 |
US20170002056A1 (en) | 2017-01-05 |
MX2016008776A (es) | 2016-11-08 |
RU2634406C1 (ru) | 2017-10-26 |
US9657084B2 (en) | 2017-05-23 |
HK1212716A1 (zh) | 2016-06-17 |
WO2015110067A1 (zh) | 2015-07-30 |
AU2015208482A1 (en) | 2016-07-14 |
KR20160085362A (ko) | 2016-07-15 |
CA2935610A1 (en) | 2015-07-30 |
BR112016015187A2 (pt) | 2018-06-05 |
JP6071099B1 (ja) | 2017-02-01 |
AU2015208482B2 (en) | 2017-02-02 |
EP3098241B1 (en) | 2017-10-25 |
ZA201604362B (en) | 2017-09-27 |
CA2935610C (en) | 2018-01-02 |
MX368442B (es) | 2019-10-02 |
JP2017505118A (ja) | 2017-02-16 |
KR101789501B1 (ko) | 2017-10-26 |
EP3098241A4 (en) | 2017-03-08 |
EP3098241A1 (en) | 2016-11-30 |
NZ721607A (en) | 2017-05-26 |
CN104804097B (zh) | 2019-02-22 |
ES2648809T3 (es) | 2018-01-08 |
CN104804097A (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA117045C2 (uk) | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування | |
MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
HK1254755A1 (zh) | 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法 | |
MX2019006340A (es) | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. | |
IL251319A0 (en) | Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use | |
GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
MX2018002315A (es) | Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos. | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
MX2019013587A (es) | Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual. | |
WO2015191666A3 (en) | Raf1 fusions | |
MX2017014140A (es) | Proteinas agonistas receptoras cd40 de cadena simple. | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
MX2016010953A (es) | Proteinas de fc multimericas. | |
CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
IL254242A0 (en) | Dual signaling fusion proteins and methods of using them to treat diseases | |
PH12015502421A1 (en) | Artificial transcription factors engineered to overcome endosomal entrapment | |
MX2019013124A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
IL265942A (en) | A nucleotide sequence expressing an exosome anchor protein for use as a component | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
NZ761611A (en) | Single-chain trail-receptor agonist proteins | |
TH1501007171A (th) | แอนติ-vegf แอนติบอดีและองค์ประกอบทางเภสัชกรรมสำหรับป้องกัน วินิจฉัย หรือรักษามะเร็ง หรือโรคที่เกี่ยวข้องกับการสร้างหลอดเลือดที่ประกอบด้วยสิ่งเดียวกัน | |
EA202092853A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM |